Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obes...(; the third parties on whom Orexigen rel...),Health

Date:9/30/2009

; the third parties on whom Orexigen relies to assist with the development programs for Empatic or Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Information included herein is based on the Company's review and evaluation of the clinical data. All conclusions and determinations contained herein are subject to the Company's further analysis of the clinical data. The ultimate determination of the safety and efficacy of Contrave and Empatic will be made by the FDA and other relevant regulatory authorities.

SOURCE Orexigen Therapeutics, Inc.

'/>"/>

SOURCE Orexigen Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
2. Orexigen(R) Therapeutics Prices Public Offering of Common Stock
3. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
4. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
5. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
6. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
7. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
8. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
9. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
10. Prime Therapeutics Hires Jacqueline Chase as Senior Vice President of Human Resources
11. Reportlinker Adds Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections) Report